Latest News - IDEXX Laboratories
Top Corporates Hub
IDEXX Laboratories
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
14.08.2026 13:34
2026-08-14. The following slide deck was published by IDEXX Laboratories, Inc.
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
13.08.2026 02:10
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710
11.08.2026 09:51
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.
IDEXX Laboratories: Worth The Premium
08.08.2026 08:00
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.
IDEXX Laboratories Q2 Earnings Call Highlights
04.08.2026 16:04
IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
04.08.2026 15:50
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say
04.08.2026 13:30
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript
04.08.2026 12:40
IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...
IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook
04.08.2026 12:15
IDEXX Laboratories Inc. (NASDAQ:IDXX) shares rose nearly 4% in pre-market trading after the veterinary diagnostics company reported second-quarter 2026 results that exceeded Wall Street expectations and increased its full-year earnings guidance.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates
04.08.2026 11:40
Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Why Is IDEXX Laboratories Stock Gaining Tuesday?
04.08.2026 11:39
IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.
IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook
04.08.2026 11:38
IDEXX Laboratories Q2 EPS beats estimates, revenue in line; raises full-year organic growth and margin outlook, shares rise 3.7% premarket.
IDEXX Laboratories Announces Second Quarter Results
04.08.2026 10:30
WESTBROOK, Maine, August 04, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.
IDEXX Laboratories Q2 2026 Earnings Call Transcript
04.08.2026 09:35
IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est
04.08.2026 06:31
IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate
04.08.2026 06:30
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from
Is IDEXX Laboratories (IDXX) Fairly Valued After Its 2025 Corporate Responsibility Report?
30.07.2026 09:09
Corporate responsibility report puts IDEXX Laboratories (IDXX) in focus IDEXX Laboratories (IDXX) recently released its 2025 Corporate Responsibility Report, drawing attention to the stock as investors assess how the company’s plans for pet diagnostics, employees, and sustainability fit into its long term outlook. See our latest analysis for IDEXX Laboratories. The recent 6.3% 30 day share price return contrasts with IDEXX Laboratories’ share price being down 15.0% year to date, while the 3...
Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings
27.07.2026 13:11
IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.
IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention
27.07.2026 12:00
Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Composite “. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]